Skip to main content

Advances in Skin Cancer Diagnosis: Using New Technologies to Identify High-Risk Patients


Click here to complete your registration.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.


Monday, September 27, 2021
8:00 - 9:00 PM ET (7:00 - 8:00 PM CT / 5:00 - 6:00 PM PT)
Hosted by: Missouri Dermatological Society

This activity is also being delivered as part of two different conferences listed below, for more information and to register, please find the links below:
Thursday, September 23, 2021
10:00 - 11:00 PM ET (9:00 - 10:00 PM CT / 4:00 - 5:00 PM PT / 8:00 - 9:00 MT)
The Utah Dermatology Conference
To register, click here.

Tuesday, September 28, 2021
7:00 - 8:00 PM ET (6:00 - 7:00 PM CT / 4:00 - 5:00 PM PT)
The Florida Society of Dermatology and Dermatologic Surgery Conference
To register, click here.

Welcome and Introduction
Improving the Diagnostic Assessment of Skin Cancers
New Strategies to Assess Risk of Recurrence
Q&A Session and Activity Roundup

Despite advances in screening and treatment, skin cancer remains a major source of morbidity and mortality in the United States. Early detection and appropriate, risk-adjusted treatment is essential to ensure optimal patient outcomes. Unfortunately, diagnosis and staging of skin cancers like melanoma and cutaneous squamous cell carcinoma (cSCC) can be challenging. Determining the risk status of newly diagnosed patients is particularly important, as it has major implications for treatment selection. Failure to appropriately assess patient risk can lead to either over or undertreatment, negatively impacting patient outcomes. In recent years, novel technologies designed to aid in diagnosis, staging, risk assessment, and treatment decision-making have emerged for melanoma and cSCC, and many more are in development. Use of these tests can help dermatologists in early identification of patients with high-risk disease who may require a more aggressive treatment approach.

This activity, Advances in Skin Cancer Diagnosis: Using New Technologies to Identify High-Risk Patients, will review emerging trends in diagnosis and risk stratification for patients with common skin cancers, including melanoma and cSCC, including discussion of current diagnostic strategies, challenges in risk stratification, and clinical applications for new molecular tests designed to identify high-risk patients and aid in treatment decision-making.

Clay J. Cockerell, MD, MBA
Clinical Professor of Dermatology and Pathology
Director Emeritus, Division of Dermatopathology
University of Texas Southwestern Medical Center
Dallas, TX

Maria L. Wei, MD, PhD
Professor of Dermatology
University of California, San Francisco
Staff Physician
San Francisco VA Health Care System
San Francisco, CA 

The intended audience for this educational initiative is dermatologists, who are the primary clinicians involved in diagnosis and staging of skin cancers.

At the conclusion of this activity, participants should be able to:

  • Describe the role of gene expression profiling in the diagnosis of patients with melanoma
  • Evaluate current and emerging staging systems for risk stratification of patients with cSCC
  • Integrate molecular testing platforms to identify patients with melanoma at high risk of recurrence


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Advances in Skin Cancer Diagnosis: Using New Technologies to Identify High-Risk Patientshas met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity
Family Medicine

Dermatologists certified by the American Board of Dermatology (ABD) must earn a minimum of 25 hours of AMA PRA Category 1 Credits™ annually. Half of these credits must be Dermatology practice-specific CME credits from accredited organizations in order to fulfill the lifelong learning component of MOC. Participation in this activity will support board certified dermatologists in contributing towards this MOC requirement set forth by the ABD.

The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

Disclosures will be made known to the participants prior to the start of the activity.

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

To ensure your computer is compatible for the live event, please perform a system check by clicking on the link or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.


  • 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
  • Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
  • 512 MB of RAM (1 GB recommended)
  • Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
  • 1.83 GHz Intel Core Duo or faster processor
  • 512 MB RAM (1 GB recommended)
  • Mac OS X 10.12, 10.13 and 10.14
  • Mozilla Firefox, Apple Safari, Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
  • The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later
  • Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods)
  • Google Android 4.4 or later
  • Apple iOS: iOS 8.1.2 or later

DSL/cable (wired connection recommended)

There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This program is supported by an educational grant from Castle Biosciences, Inc.

PCME Privacy Policy